Thomson Horstmann & Bryant Inc. grew its position in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 33.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,101 shares of the specialty pharmaceutical company’s stock after acquiring an additional 5,006 shares during the period. Thomson Horstmann & Bryant Inc. owned about 0.17% of ANI Pharmaceuticals worth $1,295,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of ANI Pharmaceuticals by 8.1% during the 2nd quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock worth $22,322,000 after buying an additional 35,722 shares during the period. Dimensional Fund Advisors LP boosted its holdings in ANI Pharmaceuticals by 25.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 424,797 shares of the specialty pharmaceutical company’s stock valued at $22,297,000 after purchasing an additional 85,529 shares during the period. Renaissance Technologies LLC boosted its holdings in ANI Pharmaceuticals by 7.0% in the 2nd quarter. Renaissance Technologies LLC now owns 297,400 shares of the specialty pharmaceutical company’s stock valued at $13,918,000 after purchasing an additional 19,400 shares during the period. Northern Trust Corp boosted its holdings in ANI Pharmaceuticals by 5.2% in the 2nd quarter. Northern Trust Corp now owns 112,905 shares of the specialty pharmaceutical company’s stock valued at $5,285,000 after purchasing an additional 5,599 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of ANI Pharmaceuticals by 868.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 104,829 shares of the specialty pharmaceutical company’s stock valued at $5,404,000 after buying an additional 94,002 shares in the last quarter. 53.24% of the stock is owned by institutional investors.
Several equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 target price for the company in a research report on Tuesday, November 7th. ValuEngine cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 20th. Canaccord Genuity reiterated a “buy” rating and set a $66.00 price objective (up from $60.00) on shares of ANI Pharmaceuticals in a research report on Monday, October 16th. BidaskClub cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 24th. Finally, TheStreet upgraded shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, November 16th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. ANI Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $71.00.
ANI Pharmaceuticals Inc (NASDAQ ANIP) traded down $6.07 during trading hours on Friday, hitting $60.87. 191,157 shares of the stock were exchanged, compared to its average volume of 97,682. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45. ANI Pharmaceuticals Inc has a 12 month low of $42.23 and a 12 month high of $74.70. The company has a market cap of $780.05, a price-to-earnings ratio of 95.11 and a beta of 2.79.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The business had revenue of $48.16 million for the quarter, compared to analyst estimates of $48.12 million. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. ANI Pharmaceuticals’s revenue was up 25.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.09 earnings per share. equities analysts expect that ANI Pharmaceuticals Inc will post 3.59 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/03/thomson-horstmann-bryant-inc-has-1-30-million-position-in-ani-pharmaceuticals-inc-anip.html.
ANI Pharmaceuticals Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.